Faculty ProfilesCatherine Koss, MD
1001 Potrero Ave
San Francisco, CA 94110
Education and Training
|Location||Degree or Training||Specialty||Date|
|Harvard College||AB||Biochemical Sciences|
|University of California, San Francisco||Fellowship, Infectious Diseases|
|University of California, San Francisco||Residency, Internal Medicine|
Awards and Honors
Early Career Award for Excellence in Clinical Research, UCSF Center for AIDS Research, 2016
TB/HIV Research Prize, co-author, International AIDS Society, 2016
Chief Fellow, Division of Infectious Diseases, University of California, San Francisco, 2013
John P. Phair Medical Student Award in infectious diseases, Northwestern University, 2009
Neil Stone Award, Northwestern University, 2009
Related Web Sites
Recent Articles (17)
Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, Horng H, Louie A, Kuncze K, Koss CA, Anderson PL, Buchbinder S, Liu A. Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study. AIDS. 2017 Aug 21.
Pintye J, Bacchetti P, Teeraananchai S, Kerr S, Prasitsuebsai W, Singtoroj T, Kuncze K, Louie A, Koss CA, Jin C, Phung N, Horng H, Sohn AH, Gandhi M. Brief Report: Lopinavir Hair Concentrations are the Strongest Predictor of Viremia in HIV-infected Asian Children and Adolescents on Second-line Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2017 Aug 18.
Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss CA, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal PJ, Aweeka FT. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther. 2017 Sep; 102(3):520-528.
Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses. 2017 Mar 02.
Natureeba P, Kakuru A, Muhindo M, Littmann E, Ochieng T, Ategeka J, Koss CA, Plenty A, Charlebois ED, Clark TD, Nzarubara B, Nakalembe M, Cohan D, Rizzuto G, Muehlenbachs A, Ruel T, Jagannathan P, Havlir DV, Kamya MR, Dorsey G. Intermittent Preventive Treatment with Dihydroartemisinin-piperaquine for the Prevention of Malaria among HIV-infected Pregnant Women. J Infect Dis. 2017 Feb 22.
Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, Koss C, Kakuru A, Mwebaza N, Kamya M, Havlir D, Dorsey G, Rosenthal P, Aweeka F . Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention. Clin Pharmacol Ther. 2017.
Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, Cohan D, Okiring J, Charlebois ED, Kamya MR, Havlir DV. Viral Suppression and Retention in Care up to 5 Years after Initiation of Lifelong ART during Pregnancy (Option B+) in Rural Uganda. J Acquir Immune Defic Syndr. 2016 Nov 04.
Gerona R, Wen A, Koss C, Bacchetti P, Gandhi M, Metcalfe J. A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2016 Jul; 20(7):991-2.
Koss CA, Natureeba P, Nyafwono D, Plenty A, Mwesigwa J, Nzarubara B, Clark TD, Ruel TD, Achan J, Charlebois ED, Cohan D, Kamya MR, Havlir DV, Young SL. Brief Report: Food Insufficiency Is Associated With Lack of Sustained Viral Suppression Among HIV-Infected Pregnant and Breastfeeding Ugandan Women. J Acquir Immune Defic Syndr. 2016 Mar 1; 71(3):310-5.
Koss CA, Jarlsberg LG, den Boon S, Cattamanchi A, Davis JL, Worodria W, Ayakaka I, Sanyu I, Huang L. A Clinical Predictor Score for 30-Day Mortality among HIV-Infected Adults Hospitalized with Pneumonia in Uganda. PLoS One. 2015; 10(5):e0126591.
Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, Horng H, Clark TD, Plenty A, Ruel TD, Achan J, Charlebois ED, Kamya MR, Havlir DV, Gandhi M. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015 Apr 24; 29(7):825-30.
Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Gandhi M, Clark TD, Nzarubara B, Achan J, Ruel T, Kamya MR, Havlir DV. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015 Jan 14; 29(2):183-91.
Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Oct 1; 67(2):128-35.
Koss CA, Baras DC, Lane SD, Aubry R, Marcus M, Markowitz LE, Koumans EH. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother. 2012 Sep; 56(9):4800-5.